为心脏心律失常开发一个机器人脉冲场碰撞系统,将机器人导航与经过验证的PFA技术相结合。 Stereotaxis and CardioFocus partner to develop a robotic pulsed field ablation system for heart arrhythmias, combining robotic navigation with proven PFA technology.

Stereotaxis 和 CardioFocus 合作开发并商业化了第一个用于治疗心律失常的机器人脉冲场消融系统，将 Stereotaxis 的机器人磁导航与 CardioFocus 的带有 CE 标志的 Centauri PFA 系统相结合。 Stereotaxis and CardioFocus have partnered to develop and commercialize the first robotic pulsed field ablation system for treating heart arrhythmias, combining Stereotaxis’s robotic magnetic navigation with CardioFocus’s CE-marked Centauri PFA System. 临床预科测试显示,综合系统会产生安全、深、耐久的损伤。 Preclinical testing shows the integrated system creates safe, deep, and durable lesions. 公司计划根据15万多个机器人程序和9 000个PFA疗法的综合经验,将技术推广到临床试验,寻求监管批准,并将该系统带给病人。 The companies plan to advance the technology into clinical trials, pursue regulatory approval, and bring the system to patients, building on their combined experience from over 150,000 robotic procedures and 9,000 PFA treatments.